<DOC>
	<DOC>NCT01173731</DOC>
	<brief_summary>The purpose of this study is to generate long-term safety, tolerability and efficacy data for AFQ056 in patients who have participated in and completed any AFQ056 phase II study in PD-LID (Parkinson's disease, L-dopa induced dyskinesias).</brief_summary>
	<brief_title>Open Label, Safety, Tolerability and Efficacy of AFQ056 in Parkinson's Patients With L-dopa Induced Dyskinesias</brief_title>
	<detailed_description />
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Dyskinesias</mesh_term>
	<mesh_term>Dyskinesia, Drug-Induced</mesh_term>
	<mesh_term>Levodopa</mesh_term>
	<criteria>Outpatients with Parkinson's disease (PD), treated with LDopa, experiencing dyskinesias who have been eligible for, participated in and completed an AFQ056 phase II core study. Surgical treatment for PD Cancer within the past 5 years (other than localized skin cancer and prostate cancer that has been effectively treated) Advanced, severe or unstable disease (other than PD) that may interfere with the study outcome evaluations Other protocoldefined inclusion/exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Parkinson Disease</keyword>
	<keyword>L-dopa</keyword>
	<keyword>Levodopa</keyword>
	<keyword>Dyskinesia</keyword>
	<keyword>involuntary movement</keyword>
	<keyword>motor complication</keyword>
</DOC>